Thrombotargets pipeline is targeted at relevant therapeutic areas that have traditionally been deprived of new and innovative drugs.
Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (Hemosta-BioplatformScreenTM), total antioxidant capacity (Oxidant-BioplatformScreenTM) and low-density lipoprotein modification (Athero-BioplatformScreenTM). With these proven proprietary new HTS Platforms, named BioPlatformScreenTM, Thrombotargets is continuously creating a novel and promising pipeline of drug candidates. Currently, TT-173 Thrombotargets’ procoagulant product is expected to enter Phase I Clinical Trials Q1-2011.
Thrombotargets has identified drug targets that serve important unmet medical needs to which we contribute with a unique biological discovery and treatment approach. The targets we select are supported by strong science and by clearly defined clinical development paths.
Thrombotargets has developed an extensive portfolio that provides the company with multiple opportunities to bring potential blockbuster products to the market.